Physician profile
Gregory R Gambla
NPI 1801832167
$4,810.59
in general payments reported to CMS, 2019-2025
35 companies · $955 in 2025
The $955 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $177 · 2021: $281 · 2022: $940 · 2023: $919 · 2024: $1,158 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,996 · Education: $35.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,996.34 |
| Education | $35.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $906.26 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $686.11 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $570.86 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $302.99 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $249.98 | 2024 | |
| Madrigal Pharmaceuticals | $191.64 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $180.45 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.23 | 2019-2023 | Trulance |
| Ironwood Pharmaceuticals, INC | $152.68 | 2022-2024 | Linzess |
| Celgene Corporation | $115.21 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $111.07 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $101.14 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $98.98 | 2020-2024 | Dificid |
| Genzyme Corporation | $84.88 | 2023-2025 | |
| Qol Medical, LLC | $80.10 | 2023-2024 | Sucraid, Sucraid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $67.96 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $65.00 | 2021-2022 | |
| Evoke Pharma, INC. | $64.65 | 2021-2023 | Gimoti |
| Intercept Pharmaceuticals, INC. | $62.08 | 2022-2025 | Ocaliva |
| Vivus LLC | $61.83 | 2019-2024 | Pancreaze |
| Ipsen Biopharmaceuticals, INC | $55.37 | 2025 | Iqirvo |
| Ucb, INC. | $50.93 | 2019 | |
| Braintree Laboratories, INC. | $49.26 | 2019-2022 | |
| Allergan, INC. | $48.77 | 2019-2020 | |
| Lilly USA, LLC | $47.45 | 2024 | Omvoh |
| Celltrion USA INC. | $40.04 | 2024-2025 | Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $38.43 | 2024 | Voquezna |
| Exact Sciences Corporation | $32.60 | 2023-2025 | Cologuard Collection Kit |
| Ardelyx, INC. | $27.04 | 2025 | Ibsrela |
| Fresenius Kabi USA, LLC | $26.49 | 2023 | |
| Ferring Pharmaceuticals INC. | $19.87 | 2023 | Rebyota |
| Shire North American Group INC | $17.42 | 2019 | |
| Echosens North America, INC. | $16.49 | 2024 | Fibroscan |
| Concordia Pharmaceuticals INC. | $11.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$62,253.88 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Gambla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.